Independent directory Public ClinicalTrials.gov records United States
Institution Directory

Clinical trials at Moffitt Cancer Center

Sites in Tampa, FL

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 3:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
710
Shown on this page
12
Current sort
Recently updated
Campus scope
Moffitt Cancer Center, Tampa, FL
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Moffitt Cancer Center, Tampa, FL. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 229–240 of 710 matching trials with a site at Moffitt Cancer Center, Tampa, FL.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Recruiting Phase 1 Interventional

Safety and Efficacy of PIPAC Using Single Agent Mitomycin in Solid Tumors

NCT07487168
Status at this site: Recruiting
Conditions
Peritoneal Carcinomatosis
Interventions
Mitomycin C (MMC), Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC)
Drug · Device
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Non Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Recurrent Non Small Cell Lung Cancer
Interventions
Tumor-infiltrating Lymphocytes (TIL), Nivolumab, Cyclophosphamide, Fludarabine, Tumor-infiltrating Lymphocyte Therapy, Interleukin-2 (IL2)
Biological · Drug · Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Active, not recruiting Phase 1Phase 2 Interventional

A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer

NCT04077099
Site status not listed — check the official record
Conditions
NSCLC
Interventions
REGN5093
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
8
States / cities
Orange, California • Washington D.C., District of Columbia • Tampa, Florida + 4 more
Conditions
Melanoma Stage III, Melanoma Stage IV, BRAF V600 Mutation
Interventions
Encorafenib Pill, Binimetinib Pill, Nivolumab
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Recruiting Phase 2 Interventional

Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy

NCT05757219
Status at this site: Recruiting
Conditions
Diffuse Large B Cell Lymphoma
Interventions
Itacitinib, Chimeric antigen receptor (CAR) T-cell therapy
Drug · Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Recruiting Not applicable Interventional Accepts healthy volunteers

Multilevel Action Toward Colorectal Cancer and Hepatitis C Education and Screening

NCT06745895
Status at this site: Recruiting
Conditions
Colorectal Cancer Screening, Hepatitis C Virus
Interventions
MATCHES
Behavioral
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
45 Years to 75 Years
Enrollment
350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Tampa, Florida
Active, not recruiting Phase 2 Interventional

Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma

NCT05524935
Site status not listed — check the official record
Conditions
Uveal Melanoma, Ocular Melanoma
Interventions
Pembrolizumab, Olaparib
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Active, not recruiting Phase 2 Interventional

Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer

NCT05751941
Site status not listed — check the official record
Conditions
Prostate Cancer, Metastatic Prostate Cancer
Interventions
Abiraterone, Enzalutamide, Apalutamide, Sipuleucel-T
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Tampa, Florida • Columbus, Ohio
Recruiting Phase 2 Interventional

Evaluation and Outcomes of SAVI Scout MD for Localized Breast Surgery

NCT07686250
Status at this site: Recruiting
Conditions
Breast Cancer
Interventions
SAVI Scout MD system
Device
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Tampa, Florida
Recruiting Not applicable Interventional

Remote Exercise and Nutritional Prehabilitation for Pancreatic Cancer

NCT06423963
Status at this site: Recruiting
Conditions
Pancreatic Cancer
Interventions
Physical Activity, Nutrition Counseling, Resistance Training
Behavioral
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Libre Del Cigarrillo: Development of an mHealth Smoking Cessation App to Extend Reach of a Validated Smoking Cessation Intervention for Spanish-speaking Smokers

NCT07754448
Site status not listed — check the official record
Conditions
Smoking Cessation
Interventions
Libre del Cigarrillo Smartphone App, Libre del Cigarrillo Printed Booklets, SmokefreeTXT en Español
Behavioral
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Tampa, Florida
Active, not recruiting Not applicable Interventional

DSC-MRI in Measuring rCBV for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma

NCT03115333
Site status not listed — check the official record
Conditions
Gliosarcoma, Recurrent Glioblastoma
Interventions
Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging
Diagnostic Test
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
58
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Castro Valley, California + 43 more

About this Moffitt Cancer Center institution page

What this page lists
ClinicalTrials.gov records that list Moffitt Cancer Center in Tampa, FL as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.